AU2001283491B2 - Macrolide formulations for inhalation and methods of treatment of endobronchial infections - Google Patents

Macrolide formulations for inhalation and methods of treatment of endobronchial infections Download PDF

Info

Publication number
AU2001283491B2
AU2001283491B2 AU2001283491A AU2001283491A AU2001283491B2 AU 2001283491 B2 AU2001283491 B2 AU 2001283491B2 AU 2001283491 A AU2001283491 A AU 2001283491A AU 2001283491 A AU2001283491 A AU 2001283491A AU 2001283491 B2 AU2001283491 B2 AU 2001283491B2
Authority
AU
Australia
Prior art keywords
macrolide antibiotic
aerosol
erythromycylamine
formulation
nebulizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001283491A
Other languages
English (en)
Other versions
AU2001283491A1 (en
Inventor
William R. Baker
Peter B. Challoner
Kay K. Huh
David M. Rycman
Ribhi M. Shawar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2001283491A1 publication Critical patent/AU2001283491A1/en
Application granted granted Critical
Publication of AU2001283491B2 publication Critical patent/AU2001283491B2/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) in Register under S187 Assignors: CHIRON CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2001283491A 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections Ceased AU2001283491B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21703200P 2000-07-10 2000-07-10
US60/217,032 2000-07-10
PCT/US2001/041328 WO2002003998A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Publications (2)

Publication Number Publication Date
AU2001283491A1 AU2001283491A1 (en) 2002-04-18
AU2001283491B2 true AU2001283491B2 (en) 2007-02-15

Family

ID=22809403

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001283491A Ceased AU2001283491B2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU8349101A Pending AU8349101A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8349101A Pending AU8349101A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Country Status (11)

Country Link
EP (1) EP1309332A2 (xx)
JP (1) JP2004502736A (xx)
KR (1) KR20030020924A (xx)
CN (1) CN1202831C (xx)
AU (2) AU2001283491B2 (xx)
BR (1) BR0112330A (xx)
CA (1) CA2415498A1 (xx)
IL (1) IL153875A0 (xx)
MX (1) MXPA03000321A (xx)
NZ (1) NZ523693A (xx)
WO (1) WO2002003998A2 (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943118B2 (en) 2004-05-17 2011-05-17 Gilead Sciences, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
AU2003205499A1 (en) * 2003-02-28 2004-09-17 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
ES2552682T3 (es) 2003-03-10 2015-12-01 Merck Sharp & Dohme Corp. Agentes antibacterianos novedosos
BRPI0411385A (pt) * 2003-06-10 2006-08-29 Astellas Pharma Inc preparação em aerossol compreendendo um invólucro que encerra uma composição em aerossol contendo um composto de macrolìdeo
US20050266578A1 (en) * 2004-05-06 2005-12-01 Gruenke Larry D Methods and systems for detection of macrolides
AU2007306344B2 (en) * 2006-10-11 2014-01-16 Laboratoires Smb S.A. Pharmaceutical anti-infective composition for inhalation.
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
WO2009055557A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2098219A1 (en) * 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
WO2010048601A1 (en) 2008-10-24 2010-04-29 Cempra Pharmaceuticals, Inc. Biodefenses using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2637072T3 (es) * 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
RU2608390C2 (ru) 2010-05-20 2017-01-18 Семпра Фармасьютикалз, Инк. Способы получения макролидов и кетолидов, и промежуточных соединений для их получения
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
RU2658050C2 (ru) 2012-03-27 2018-06-19 Семпра Фармасьютикалз, Инк. Парентеральные составы для введения макролидных антибиотиков
US9861616B2 (en) 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
FI20205368A1 (en) * 2020-04-07 2021-10-08 Aalto Univ Foundation Sr FORMULATION
CN114796116A (zh) * 2022-05-17 2022-07-29 中山大学附属第六医院 一种阿奇霉素吸入剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037190A1 (de) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stabile, konzentrierte, lokalverträgliche erythromycylamin-lösungen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60209517A (ja) * 1984-04-03 1985-10-22 Unitika Ltd エアゾ−ル組成物
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
JPH01283225A (ja) * 1988-05-10 1989-11-14 Toyo Jozo Co Ltd 牛呼吸器感染症治療用エアゾール製剤およびそれを用いる治療方法
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
CA2153553A1 (en) * 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
DE69814428T2 (de) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
CZ2001690A3 (cs) * 1998-08-28 2002-04-17 Eli Lilly And Company Způsob podávání inzulinotropních peptidů
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
SI20959A (sl) * 1998-12-17 2003-02-28 Pathogenesis Corporation Metoda za zdravljenje hudega kroničnega bronhitisa (bronhiektazije) z aerosoliziranimi antibiotiki
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037190A1 (de) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stabile, konzentrierte, lokalverträgliche erythromycylamin-lösungen

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943118B2 (en) 2004-05-17 2011-05-17 Gilead Sciences, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
US8361444B2 (en) 2004-05-17 2013-01-29 Gilead Sciences, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
US8409549B2 (en) 2004-05-17 2013-04-02 Gilead Sciences, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
US8980226B2 (en) 2004-05-17 2015-03-17 Gilead Sciences, Inc. Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections

Also Published As

Publication number Publication date
CA2415498A1 (en) 2002-01-17
WO2002003998A2 (en) 2002-01-17
AU8349101A (en) 2002-01-21
BR0112330A (pt) 2003-10-07
KR20030020924A (ko) 2003-03-10
WO2002003998A3 (en) 2002-06-13
CN1471401A (zh) 2004-01-28
MXPA03000321A (es) 2003-06-06
JP2004502736A (ja) 2004-01-29
IL153875A0 (en) 2003-07-31
CN1202831C (zh) 2005-05-25
EP1309332A2 (en) 2003-05-14
NZ523693A (en) 2004-08-27

Similar Documents

Publication Publication Date Title
AU2001283491B2 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2001283491A1 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US7696178B2 (en) Optimised formulation of tobramycin for aerosolization
US20050129623A1 (en) Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections
US7427633B2 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
KR20040075897A (ko) 아미노글리코시드의 폐 전달
BRPI0707904A2 (pt) disfarce gustativo de fluoroquinolonas aerossolizadas
AU2002319226A1 (en) Optimised formulation of tobramycin for aerosolization
CA2717201A1 (en) Macrolide compositions having improved taste and stability
CA2530774C (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US20040022740A1 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20120128728A1 (en) Compositions Comprising Amphotericin B
US8513204B2 (en) Compositions comprising amphotericin B, mehods and systems
AU2009233632B2 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired